drugset / Trial / NCT05325164

Methadone for 'Adenocarcinopathic' Pain Treatment

NCT05325164

RandomizedParallel-groupDouble-blindTreatment

Summary

Methadone is an opioid that has been used for over 80 years to treat various types of pain, including cancer pain. Despite its increasing popularity as a co-analgesic and first-line treatment for cancer pain, there remain some outstanding questions regarding its use in treating cancer pain, such as its efficacy compared to other opioids and its appropriateness as a first-line treatment. The investigators will conduct a Vanguard Randomized Clinical Trial (RCT) to estimate the efficacy of methadone compared to morphine for the treatment of a newly defined type of cancer pain, which the investigators have termed 'adenocarcinopathic' pain (ACPP).

Timeline

Start
2022-09
Primary completion
2023-08
Completion
2023-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methadone Other / unclassified 2.5 mg Oral
Subject Methadone Other / unclassified 3 mg Oral
Comparator Morphine Other / unclassified 12.5 mg Oral
Comparator Morphine Other / unclassified 15 mg Oral

Indications